We have located links that may give you full text access.
Thyroid cytology in Pakistan; an institutional audit of AUS/FLUS category.
BACKGROUND: Fine needle aspiration cytology (FNAC) along with the thyroid ultrasound is an important tool in evaluation of the thyroid nodules & help in further management of these patients i-e decision of surgical intervention vs follow-up. The Bethesda system for reporting thyroid cytopathology (TBSRTC) category III of Atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) has risk of malignancy ranging from 5-15%. The aim of the present study was to describe the frequency of AUS/FLUS in thyroid gland FNACs and the surgical outcomes of these cases.
METHODS: The integrated laboratory management system (ILMS) retrieved the thyroid FNACs from 2010-2018 and subsequent surgical pathology specimens. For the AUS/FLUS cases, data regarding patients' demographics, cytology and histological diagnoses were recorded. The results were tabulated as the overall frequency of AUS/FLUS in thyroid FNACs, cytohisto correlation (benign and malignant) and risk of malignancy (ROM).
RESULTS: During 9-years, 256 (10.9%) cases out of 2342 thyroid FNACs were reported as AUS/FLUS at our institution. Mean age was 43.5 year. Majority (70.3%) of patients were female. Seventy-two of 104 resection specimens (69.2%) were reported benign and 32 cases (30.7%) had malignant diagnosis. Upper-bound ROM was 30.7% (32 cases with malignant diagnosis out of 104 resection specimens). Lower-bound ROM was calculated as 12.5% (32 cases with malignant diagnosis out of 256 total AUS diagnosis).
CONCLUSION: The AUS/FLUS category of thyroid cytology & associated risk of malignancy remain an evolving area of thyroid cytology. Individual institution should monitor the frequency & include ROM in the dashboard indicators to remain within the recommended range.
METHODS: The integrated laboratory management system (ILMS) retrieved the thyroid FNACs from 2010-2018 and subsequent surgical pathology specimens. For the AUS/FLUS cases, data regarding patients' demographics, cytology and histological diagnoses were recorded. The results were tabulated as the overall frequency of AUS/FLUS in thyroid FNACs, cytohisto correlation (benign and malignant) and risk of malignancy (ROM).
RESULTS: During 9-years, 256 (10.9%) cases out of 2342 thyroid FNACs were reported as AUS/FLUS at our institution. Mean age was 43.5 year. Majority (70.3%) of patients were female. Seventy-two of 104 resection specimens (69.2%) were reported benign and 32 cases (30.7%) had malignant diagnosis. Upper-bound ROM was 30.7% (32 cases with malignant diagnosis out of 104 resection specimens). Lower-bound ROM was calculated as 12.5% (32 cases with malignant diagnosis out of 256 total AUS diagnosis).
CONCLUSION: The AUS/FLUS category of thyroid cytology & associated risk of malignancy remain an evolving area of thyroid cytology. Individual institution should monitor the frequency & include ROM in the dashboard indicators to remain within the recommended range.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app